Hurlburt Elizabeth 4

What Happened

• Elizabeth Hurlburt, Chief Operating Officer of CorMedix, was granted/awarded 36,006 shares (transaction code A) on February 4, 2026. The filing reports an acquisition price of $0 and a reported total value of $0 for the award. This was an award of performance stock units converted to shares upon meeting a performance condition, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-04 (Form 4 filed 2026-02-06). Filing appears timely (within the standard two-business-day window).
• Transaction type/code: A (award/grant/acquisition).
• Shares issued: 36,006 shares; reported acquisition price $0 (award).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The award reflects achievement of PSUs for the first of three performance periods (from PSUs granted Jan 2, 2025); shares remain subject to time-based vesting per the Compensation Committee’s determination.

Context

• These were performance-based awards (PSUs) recognized as achieved for one performance period; however, the shares are still subject to time-based vesting conditions and may not be immediately tradable. Awards like this are compensation-related and do not carry the same straightforward market-sentiment signal as open-market purchases or sales.